Knauer M F, Soreghan B, Burdick D, Kosmoski J, Glabe C G
Department of Molecular Biology and Biochemistry, University of California, Irvine 92717.
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7437-41. doi: 10.1073/pnas.89.16.7437.
The A4 or beta protein is a peptide that constitutes the major protein component of senile plaques in Alzheimer disease. The A4/beta protein is derived from a larger, transmembrane amyloid precursor protein (APP). The putative abnormal processing events leading to amyloid accumulation are largely unknown. Here we report that a 42-residue synthetic peptide, beta 1-42, corresponding to one of the longer forms of the A4/beta protein, accumulates in cultured human skin fibroblasts and is stable for at least 3 days. The peptide appears to accumulate intracellularly, since it does not accumulate under conditions that prevent endocytosis and accumulation is correlated with the acquisition of resistance to removal by trypsin digestion. This intracellular accumulation is also correlated with the ability of the peptide to aggregate as determined by SDS/polyacrylamide gel electrophoresis. At low concentrations of the beta 1-42 peptide, which favor the nonaggregated state, no accumulation is observed. Shorter peptide analogs (28 or 39 residues) that are truncated at the C terminus, which lack the ability to aggregate in SDS gels, fail to accumulate. The accumulated intracellular beta 1-42 peptide is in an aggregated state and is contained in a dense organellar compartment that overlaps the distribution of late endosomes or secondary lysosomes. Immunofluorescence of the internalized peptide in permeabilized cells reveals that it is contained in granular deposits, consistent with localization in late endosomes or secondary lysosomes. Sequence analysis indicates that some of the internalized peptide is subject to N-terminal trimming. These results suggest that the aggregated A4/beta protein may be resistant to degradation and suggest that the A4/beta protein may arise, at least in part, by endosomal or lysosomal processing of APP. Our results also suggest that relatively nonspecific proteolysis may be sufficient to generate the A4/beta protein if this part of APP is selectively resistant to proteolysis.
A4或β蛋白是一种肽,它构成了阿尔茨海默病老年斑的主要蛋白质成分。A4/β蛋白源自一种更大的跨膜淀粉样前体蛋白(APP)。导致淀粉样蛋白积累的假定异常加工事件在很大程度上尚不清楚。在此我们报告,一种42个氨基酸残基的合成肽β1-42,对应于A4/β蛋白的较长形式之一,在培养的人皮肤成纤维细胞中积累,并且至少3天保持稳定。该肽似乎在细胞内积累,因为在防止内吞作用的条件下它不会积累,且积累与获得对胰蛋白酶消化去除的抗性相关。这种细胞内积累也与该肽通过十二烷基硫酸钠/聚丙烯酰胺凝胶电泳测定的聚集能力相关。在有利于非聚集状态的低浓度β1-42肽时,未观察到积累。在C末端截短的较短肽类似物(28或39个氨基酸残基),缺乏在SDS凝胶中聚集的能力,不能积累。积累的细胞内β1-42肽处于聚集状态,并包含在一个与晚期内体或次级溶酶体分布重叠的致密细胞器区室中。通透细胞中内化肽的免疫荧光显示它包含在颗粒沉积物中,这与在晚期内体或次级溶酶体中的定位一致。序列分析表明一些内化肽经历了N末端修剪。这些结果表明聚集的A4/β蛋白可能抗降解,并表明A4/β蛋白可能至少部分地由APP通过内体或溶酶体加工产生。我们的结果还表明,如果APP的这一部分对蛋白水解有选择性抗性,相对非特异性的蛋白水解可能足以产生A4/β蛋白。